US FDA advisors to hold September meeting on long-term safety of popular bone drugs
This article was originally published in SRA
Executive Summary
Two advisory committees of the US Food and Drug Administration are set to hold a public meeting on 9 September to discuss the benefits and risks of using bisphosphonate over a long term period to treat and prevent osteoporosis1,2.